Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Imfinzi approved in US for resectable lung cancer

16 August 2024  Imfinzi approved in the US for the treatment of resectablenon-small cell lung cancer before and after surgeryBased on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk ofrecurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma

Heimstaden Bostad AB Q2 2024 Results

Highlights (figures in brackets refer to same quarter last year):  ·The Privatisation Plan continued to deliver in line with ramp-up expectations as H1 total sales reached SEK 2,818 million. In the second quarter of 2024, 363 units were sold with a 29.0% premium to book value  ·The NOI margin improved to 71.5% (69.0%) and the LTM NOI margin was 68.4% (66.0%)  ·NOI growth offset slightly expanding yields, leading to a 0.4% (-2.1%) increase in property values  ·Rental income at SEK 3,938 million (3,707) and like-for-like rental growth of 5.1% (5.6%)  ·Real

Heimstaden AB Q2 2024 Results

Highlights (figures in brackets refer to same quarter last year):  ·The Privatisation Plan continued to deliver in line with ramp-up expectations as H1 total sales reached SEK 2,818 million. In the second quarter of 2024, 363 units were sold with a 29.0% premium to book value  ·The NOI margin improved to 71.4% (69.0%) and the LTM NOI margin was 68.3% (66.2%)  ·NOI growth offset slightly expanding yields, leading to a 0.4% (-2.1%) increase in property values  ·Rental income at SEK 3,943 million (3,800) and like-for-like rental growth of 5.1% (5.7%)  ·Real

Viking Line: Half year financial report January - June 2024

Viking Line Abp                           HALF YEAR FINANCIAL REPORT                 15.08.2024, 9.00 AMA half-year characterized by weaker demand   JANUARY-JUNE 2024 (compared to January–June 2023) · Sales amounted to EUR 219.1 M (EUR 226.3 M). · Other operating revenue was EUR 0.6 M (EUR 8.9 M, including the EUR 8.6 M capital gain from the sale of Rosella.)  · Operating income totalled EUR -4.3 M (EUR 17.1 M, including the EUR 8.6 M capital gain from the sale of Rosella.)  · Net financial items were EUR -8.1 M (EUR -7.7 M).  · Income before taxes totalled EUR -

Ranplan Group AB – Interim Report Jan - Jun 2024

2024-08-16 08:00 CET The period in summary First half of 2024 (first half of 2023) · Total income amounted to SEK 14.0 million (11.2 million)[1] · Net sales amounted to SEK 6.6 million (6.2 million) · Total revenues amounted to SEK 11.4 million (8.1 million) · Operating income amounted to SEK -5.5 million (-14.5 million) · Net income amounted to SEK -6.6 million (-15.8 million) · Earnings per share amounted to SEK -0.14 (-0.51) · Cash flow from operations amounted to -SEK 3.6 million (-10.7 million) · Cash at the end of the period amounted to SEK 2.4 million (

Interim report January – June 2024

Increased net sales after acquisition and strong cash flowApril – JUNe 2024 •    Net sales amounted to SEK 395.9 million (274.6), an increase of 44%. •    Net sales for comparable segments decreased by SEK 10.4 million, adecrease by 4%.•    Operating profit amounted to SEK 25.8 million (32.0), a decrease by 19%. •    The operating margin decreased to 6.5% (11.6).•    Non-recuring costs are included in the operating profit with SEK -9.0million. In the comparing quarter electricity grant of SEK 5.5 million wasreceived.•    The profit for the period amounted to SEK 16.5

Cereno Scientific expands patent protection for PAH drug candidate CS1’s third patent family in Brazil

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a new granted patent in CS1’s third patent family has been issued in Brazil.“I am happy to announce another granted patent for our leading drug candidate, CS1, in Phase II development for the rare disease Pulmonary Arterial Hypertension (PAH). We are continuously working to expand the patent protection for our assets. The newly granted patent is Cereno’s first in Brazil, a major pharmaceutical market, and will play an

Kamux Corporation’s Half Year Financial Report for January 1—June 30, 2024: Revenue decreased and adjusted operating profit decreased significantly, a weak Q2 in Sweden

Kamux Corporation, Half Year Financial Report, 16.8.2024 at 9:00 Kamux Corporation’s Half Year Financial Report for January 1—June 30, 2024: Revenue decreased and adjusted operating profit decreased significantly, a weak Q2 in Sweden This is a summary of Kamux Corporation’s Half Year Financial Report for January 1—June 30, 2024. The complete report is attached to this release and is also available at the company website at www.kamux.com. The figures in parentheses refer to the comparison period, i.e., the same period in the previous year, unless stated otherwise. April–June in

Polymer Factory Sweden AB (publ) Interim Report Q2 2024

The period in summary Second quarter, April-June 2024 · Products from the SpheriCal® platform were featured in a scientific article, co-authored by Polymer Factory · The Company exhibited and presented at the ASMS conference in Anaheim, USA in June · The Company launched SpheriCal® for IM-MS · Trading of the Company's share moved from Spotlight Stock Market to Nordic SME on Nordic Growth Market Year to date, January-June 2024 · The Company entered into a distribution agreement regarding SpheriCal® · Result for the period increased compared to same period last

Delårsrapport Q2 2024

1 JANUARI – 30 JUNI 2024FLOWSCAPE TECHNOLOGY AB (publ),ORG.Nr. 556725-4866Styrelsen och verkställande direktören för Flowscape Technology AB avger härmed rapport för perioden januari – juni 2024. Belopp anges i tusentals kronor. Siffror inom parentes avser motsvarande period föregående år This information is only available in SwedishJanuari – juni i korthet, concern Andra kvartalet (April-juni) · Nettomsättningen uppgick till 10 391 (11 668) TSEK · Rörelseresultatet före avskrivningar uppgick till -212 (1 307) TSEK · Resultat efter finansiella poster uppgick till -2

Essity’s targets to reach net-zero emissions validated by Science Based Targets initiative

Hygiene and health company Essity’s targets to reach net zero greenhouse gas emissions by 2050 have been validated by Science Based Targets initiative (SBTi). The validation applies to all near- and long-term targets in Scope 1, 2, and 3. The roadmap has been developed as part of the U.N. Global Compact’s “Business Ambition for 1.5°C”.Essity’s long-term target is to achieve net zero emissions across the value chain no later than 2050. The company's near-term Scope 1 and 2 target (energy use within the company and purchased energy) is to reach a 35% reduction by 2030 and the near-term Scope

Raute’s fully owned Hiottu Oy to be merged into Raute Corporation

RAUTE CORPORATION PRESS RELEASE 16 AUGUST 2024 AT 9 A.M.  Raute’s fully owned Hiottu Oy to be merged into Raute Corporation   Raute's Board of Directors has approved a merger plan according to which the company's fully owned subsidiary Hiottu Oy will be merged into Raute Corporation.   The merger is expected to take place on 31 December 2024.   Raute Corporation acquired 80 percent of the shares of Hiottu Oy in 2020 and redeemed the remaining 20 percent in 2023. Hiottu Oy has brought strong digitalization expertise to Raute, especially in machine vision and AI

Mandatum Asset Management Growth Equity II fund invests in Integrata, an HR and payroll technology company

Mandatum Oyj, Press release 16 August 2024, 9:00 a.m. EEST Mandatum Asset Management’s growth investment strategy has invested in Integrata, a Finnish growth company. The investment boosts Integrata’s international growth and the development of its technology solutions. This is the third investment made by the MAM Growth Equity II fund. The MAM Growth Equity strategy focuses on the scale-up phase of Finnish and Nordic growth companies. It takes part in exceptional growth stories by being an active owner and providing expertise, networks and flexible growth capital for companies with a

Grand opening of Eidra’s new office in central Stockholm

STOCKHOLM 2024-08-16. The consultancy collective Eidra just moved into their new headquarters in central Stockholm. The office, located in a historical building from 1934, can be found in the new area Grev Tureplan at the intersection of Grev Turegatan and Birger Jarlsgatan. It is a carefully renovated building of 8000 sqm that will act as a hub for Eidra’s 18 group companies, their 1200 employees and their clients.“We really look forward to the incredible moments that we know we’ll share together in this space. And most of all, we’re excited to see the impact this will have on future

Issue of £3.5 million of New Convertible Loan Notes

16 August 2024 Everest Global plc (“Company”) Issue of £3.5 million of New Convertible Loan Notes   The directors of the Company are pleased to announce that on 15 August 2024 the Company constituted a loan note instrument pursuant to which the Company may issue up to £50 million loan notes in tranches of integral multiples of £250,000 at any time. Each tranche of loan notes will have an initial term of 3 years from the date of the certificate being issued to the relevant noteholder (the “Loan Note Instrument”). Pursuant to the terms of the Loan Note Instrument the Company

Interim report April - June 2024

SECOND QUARTER (APRIL– JUNE 2024)       · Order intake SEK 290.3 M (239.2) · Net sales SEK 318.9 M (239.5) · Operating profit SEK 79.3 M (18.2) · Profit after tax SEK 61.4 M (10.9) · Earnings per share before/after dilution SEK 1.79 (0.32) · Cash flow from operating activities SEK 154.6 M (67.2) · Order backlog SEK 1,790.5 M (1,954.9) at the end of the period HALF-YEAR (JANUARY– JUNE 2024) · Order intake SEK 528.8 M (445.8) · Net sales SEK 576.1 M (469.6) · Operating profit SEK 125.1 M (41.9) · Profit after tax SEK 98.1 M (28.5) · Earnings per

Notice of Record Date - Special General Meeting

Hamilton, Bermuda, August 16, 2024 – Paratus Energy Services Ltd. (the “Company”) advises that a Special General Meeting of the Company will be held on September 5, 2024 (“Meeting”), to approve a reduction of the Company’s share premium account. The purpose of the reduction is primarily to increase the ability of the Company to make distributions to its Shareholders. The record date for voting at the Meeting is set to August 16, 2024. A copy of the Notice and associated information will be distributed and made available prior to the Meeting. This information is subject to the disclosure

Casinoble Canada Unveils Redesigned Website with Enhanced Menus for Improved User Navigation and Experience

Toronto, ON, August 16, 2024 – Casinoble Canada, one of the leading affiliate marketing site for online gambling, proudly announces the launch of its newly redesigned website. This significant update features enhanced menus and improved user navigation, aimed at providing Canadian online gamblers with a more seamless and engaging experience.In response to user feedback and evolving industry standards, Casinoble Canada's revamped website offers a modern design and intuitive layout that ensures easy access to the wealth of resources available. The redesigned site is part of Casinoble's

Kemira renews operating model and Management Board to accelerate growth strategy

Kemira Oyj, Stock Exchange Release, 16 August, 2024 at 8.30 EESTKemira renews operating model and Management Board to accelerate growth strategy Kemira announces changes to its operating model to better meet profitable growth ambitions and moves to three externally reported business units. The planned changes aim to increase customer centricity, strategic focus, speed of delivery and accelerate growth and shareholder value creation. As a result of the changes, both the composition and the name of Kemira’s Management Board will change. Kemira’s Group Leadership Team from January 1,

Archer Limited: Archer reports continued quarterly growth

Hamilton Bermuda (August 16th, 2024)In the second quarter, Archer continued to deliver strong growth with revenue of $309 million and EBITDA of $32.8 million, representing a YOY-growth of 5% and 9% respectively. Year to date, Archer’s EBITDA has grown by 15% over the same period last year, highlighting Archer’s continued ability to grow revenue while improving margins.  Second Quarter 2024 Highlights: · Revenue of $309 million; up 5% YOY · EBITDA of $32.8 million, up 9% YOY · H1 EBITDA of $63.7 million, up 15% YOY · Positive net income in second quarter of $1.0 million ·

Ambea’s interim report April – June 2024

Continued earnings improvement, new residential facilities and acquisitions.CEO comments. In Vardaga, the positive earnings growth continued, driven by increased occupancy and operational improvements. During the quarter, we opened two new residential facilities and welcomed new care receivers to Villa Djäknegatan in Uppsala and Villa Bromsten in Stockholm. During the period, we also signed agreements for two new nursing homes located in Stockholm and Växjö. The homes are scheduled to open in 2027 and add 240 new elderly care places. The positive trend also continued for Stendi. The

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million following the agreement with Orion Corporation to market and sell Flexilev® and OraFID® in Europe is included.During the first six months of 2024, Navamedic has delivered on its strategy across the

There are no items matching the current filter
There are no more items matching the current filter
Back to top